Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Organon NuvaRing contraceptive approved

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Organon's NuvaRing vaginal contraceptive ring, approved Oct. 3, is a non-biodegradable, flexible ring delivering a daily dose of 0.015 mg ethinyl estradiol and 0.120 mg etonogestrel. NuvaRing is inserted once a month and kept in place for three weeks. Under a pre-launch distribution program, Organon will offer the product free of charge for six months to 30,000 women. The company is expanding manufacturing facilities in the Netherlands and expects to have supplies for full product launch by May or June. The firm said that NuvaRing will be priced competitively to Pharmacia's monthly injection contraceptive Lunelle, which has an average wholesale price of $24.95 per monthly injection
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS001647

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel